Form 4: Privia Health Director Jaewon Ryu Receives Significant Equity Grant

Privia Health Group, Inc. Director Jaewon Ryu was granted 8,396 restricted stock units as part of the company's 2021 Omnibus Incentive Plan.

Summary

• Jaewon Ryu, a Director of Privia Health Group, Inc. (PRVA), reported an acquisition of securities on May 21, 2025.
• The transaction involved the acquisition of 8,396 shares of Common Stock, $0.01 par value per share, in the form of restricted stock units (RSUs).
• The acquisition price for these RSUs was $0, indicating they were granted as compensation rather than purchased.
• These restricted stock units were granted under the Issuer's 2021 Omnibus Incentive Plan.
• The RSUs are scheduled to vest on the earlier of (i) the day immediately preceding the Company's 2026 annual meeting of stockholders or (ii) the first anniversary of the grant date (May 21, 2026).
• Following this transaction, Jaewon Ryu's beneficial ownership stands at 38,647 shares.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive event as it aligns the director's interests with long-term shareholder value, although it is a routine compensation practice and does not indicate extraordinary performance.

Positives

• The grant of 8,396 restricted stock units to Director Jaewon Ryu aligns his interests with those of shareholders, incentivizing long-term performance and value creation.
• The equity grant is part of the company's established 2021 Omnibus Incentive Plan, indicating a structured and transparent approach to executive and director compensation and retention.

Negatives

• The restricted stock units do not provide immediate liquidity to the director until they vest, which is a common characteristic of such equity awards.

Future Outlook

The restricted stock units granted to Director Jaewon Ryu are scheduled to vest on the earlier of the day immediately preceding the Company's 2026 annual meeting of stockholders or the first anniversary of the grant date (May 21, 2026).

Industry Context

This Form 4 filing reflects a standard practice in corporate governance where directors receive equity compensation to align their interests with long-term shareholder value. Such grants are common across various industries, including healthcare services, to incentivize leadership and retention.

Comparison to Industry Standards

• Equity grants to directors, such as restricted stock units, are a common form of compensation in publicly traded companies across various sectors, including healthcare.
• While the specific size of the grant (8,396 RSUs) would typically be benchmarked against peer companies like One Medical (ONEM), Oak Street Health (OSH), or Cano Health (CANO) to assess competitiveness and alignment with industry norms for director compensation, this document does not provide the necessary context for such a detailed comparison.

Corporate Governance

Related Party Transactions

• The grant of 8,396 restricted stock units to Jaewon Ryu, a Director of Privia Health Group, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The equity grant to a director aligns management's long-term interests with shareholder value, potentially leading to improved company performance and a focus on sustainable growth.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation strategy that can influence overall company culture and retention of key personnel, particularly at the leadership level.

Next Steps

• Vesting of the 8,396 restricted stock units on the earlier of the day immediately preceding the Company's 2026 annual meeting of stockholders or May 21, 2026.

Key Dates

Recommendation

Keywords

Privia Health, PRVA, Jaewon Ryu, Form 4, SEC filing, insider transaction, restricted stock units, RSU, equity grant, director compensation, corporate governance